Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$19.25 CAD
Change Today +0.83 / 4.51%
Volume 400.0
NDQ On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ GM
Frankfurt
As of 3:59 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

novadaq technologies inc (NDQ) Snapshot

Open
C$18.93
Previous Close
C$18.42
Day High
C$19.25
Day Low
C$18.93
52 Week High
04/3/14 - C$27.39
52 Week Low
10/17/14 - C$11.68
Market Cap
1.1B
Average Volume 10 Days
2.8K
EPS TTM
C$-0.73
Shares Outstanding
55.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVADAQ TECHNOLOGIES INC (NDQ)

Related News

No related news articles were found.

novadaq technologies inc (NDQ) Related Businessweek News

No Related Businessweek News Found

novadaq technologies inc (NDQ) Details

Novadaq Technologies Inc. develops, manufactures, and markets fluorescence imaging products and therapeutic devices for use by surgeons in the operating room and other clinical settings in the United States and internationally. The company’s proprietary imaging platform is used to visualize blood vessels, nerves, and the lymphatic system during surgical procedures. It offers SPY Elite imaging system for use in coronary artery bypass graft surgery, cardiovascular surgery, plastic surgery, reconstructive surgery, microsurgery, organ transplant, and gastrointestinal surgery. The company’s PINPOINT endoscopic fluorescence imaging system is used for traditional endoscope and to obtain fluorescence images on demand or in a simultaneous imaging mode during minimally invasive surgery; and LUNA imaging system enables physicians treating chronic wounds to distinguish perfused and non-perfused tissue during the treatment of diabetic foot ulcers, pressure sores, and other serious chronic non-healing wounds. It also provides DermACELL tissue products for use in breast reconstruction surgeries, as well as in the treatment of diabetic foot ulcers and chronic non-healing wounds. In addition, the company offers Firefly imaging systems for use in robotic surgery; SPY analysis toolkit, a post-processing software that allows physicians to enhance and apply objective analysis tools to SPY Elite and LUNA images; and CO2 heart laser system for transmyocardial revascularization. Novadaq Technologies Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

Founded in 2000

novadaq technologies inc (NDQ) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $364.1K
Co-Founder, Senior Vice President and General...
Total Annual Compensation: $218.5K
Chief Financial Officer
Total Annual Compensation: $174.8K
Compensation as of Fiscal Year 2013.

novadaq technologies inc (NDQ) Key Developments

Novadaq Technologies Inc. Announces Appointment of Patrice E. Merrin to Board of Directors

Novadaq Technologies Inc. announced that Patrice E. Merrin has been appointed to the company's Board of Directors. She is currently a non-executive director of Glencore PLC and Stillwater Mining Company. Ms. Merrin was Chairman of the Board of CML HealthCare Inc., from 2011 to 2013, having served as a director since 2008. She was a director of Ornge from 2012 to 2015.

Novadaq Technologies Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 11:15 AM

Novadaq Technologies Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 11:15 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Arun Menawat, Chief Executive Officer, President and Director.

Novadaq Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for the Year Ending December 31, 2015

Novadaq Technologies Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the three months ended December 31, 2014, the company reported revenues of $13.0 million an increase of 21% from $10.7 million in the fourth quarter of 2013. Significantly lower than expected capital sales of SPY Elite achieved by its former partner, LifeCell Corporation, combined with the negative impact of inventory adjustments resulting from the termination of NOVADAQ's SPY Elite distribution agreement with LifeCell, resulted in SPY Elite product revenues declining 41% to $2.5 million in fourth quarter of 2014 from $4.2 million in fourth quarter of 2013. Net loss was $17.6 million, or $0.32 loss per share, compared with a net loss of $2.7 million, or $0.05 loss per share a year ago. Loss from operations was $10,209,787 against $3,266,504 a year ago. Loss before income taxes was $17,517,114 against $2,782,436 a year ago. Cash used in operating activities was $10,150,751 against $2,418,312 a year ago. Purchase of property and equipment was $1,161,944 against $1,958,312 a year ago. Purchase of intangible assets was $6,000,000 against $39,853 a year ago. For the year ended December 31, 2014, the company's revenues were $46.6 million, an increase of 33% from $3 5.0 million in 2013. Net loss was $24.4 million, or $0.44 loss per share, compared to $22.3 million, or $0.47 loss per share, in 2013. Loss from operations was $22,718,922 against $7,237,816 a year ago. Loss before income taxes was $24,304,059 against $22,302,095 a year ago. Cash used in operating activities was $25,132,815 against $5,301,758 a year ago. Purchase of property and equipment was $6,399,928 against $6,424,498 a year ago. Purchase of intangible assets was $12,368,753 against $2,517,267 a year ago. The company anticipates its full year revenue for the fiscal year ending December 31, 2015 to be approximately $65 million, representing total year-over-year revenue growth of approximately 40%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NDQ:CN C$19.25 CAD +0.83

NDQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CryoLife Inc $10.07 USD +0.09
View Industry Companies
 

Industry Analysis

NDQ

Industry Average

Valuation NDQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.3x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVADAQ TECHNOLOGIES INC, please visit www.novadaq.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.